Clinical Trial: HIPEC Using High Intra-abdominal Pressure
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Effects of High Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin During HIPEC
Brief Summary:
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapy for peritoneal carcinomatosis (PC) of various origins. Rather than the pharmacokinetic advantage, the uptake of chemotherapy by tumor tissue has been proposed as the best pharmacologic endpoint to assure the efficacy of HIPEC.
The primary endpoints of the present phase II randomized study are to test whether the increased intra abdominal pressure (IAP) during HIPEC could:
- enhance the penetration of cisplatin into the residual neoplastic and normal tissues;
- elicit changes on pharmacokinetic advantage of cisplatin.
Secondary endpoints are to evaluate the:
- impact of high IAP on intraoperatory hemodynamic and respiratory parameters;
- impact on short-term surgical outcomes (in hospital stay, morbidity, mortality).
Patients affected by PC from colorectal cancer or pseudomyxoma peritonei, submitted to complete cytoreduction (residual disease <2.5mm) would be eligible for the study. HIPEC will be performed using closed abdomen technique and cisplatin + mitomycin-C. Patients will be randomly assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be measured using bladder catheter. High IAP will be obtained increasing the volume of perfusate.
Thirty-eight patients (19 in each study groups) will be enrolled in 30 months. The randomized groups will be stratified according to tumor type.
Detailed Summary:
Patients affected by peritoneal metastasis from colorectal cancer or pseudomyxoma peritonei, submitted to complete cytoreduction (residual disease <2.5mm) would be eligible for the study. Residual and resectable tumour nodules of 0.5 to 1.0 cm will be left behind after the cytoreduction and they will be collected at the end of HIPEC for the purpose of this study. HIPEC will be performed using closed abdomen technique and cisplatin (42mg/L of perfusate) + mitomycin-C (3.3mg/m2/L of perfusate) for 60 minutes, at 42.5°C. Patients will be randomly assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be measured using bladder catheter. Patients of high IAP group will be strictly monitored during the perfusion regarding hemodynamic/respiratory parameters. During the HIPEC, perfusate and blood samples will be collected every 10 minutes. Additional samples of arterial blood will be collected at 70, 90,120,180 and 240 minutes. After the completion of HIPEC residual tumor tissues, normal peritoneum and muscular fascia will be sampled for determination of cisplatin concentration.
Blood samples will be immediately centrifuged to separate plasma. An aliquot of plasma will be stored at -30°C for total platinum determination. Another aliquot will be ultrafiltered by centrifugation through a membrane with a cut-off 5000 Da for ultrafilterable platinum determination. The ultrafiltrate will be stored at -30°C until analysis.
Perfusate samples will follow the same procedure of blood samples. Tissues samples will be stored at -80°C until analysis. Platinum determination will be performed using an Inductive Coupled Plasma Mass Spectrometry (ICP-MS) system by Thermo Scientific after preparing calibration curves with atomic platinum. Fluid samples simply dilute before ICP-MS examination while tissu
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Current Primary Outcome:
- Tumor tissue concentration of cisplatin [ Time Frame: collected within 15 minutes after the completion of HIPEC ]residual neoplastic tissue concentration of cisplatin measured in ng/mg
- Normal tissue concentration of cisplatin [ Time Frame: collected within 15 minutes after the completion of HIPEC ]tissue concentration of cisplatin measured in ng/mg in peritoneum of mesentery and rectal muscle fascia
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Pharmacokinetic advantage [ Time Frame: During the HIPEC up to 1 hour from the completion of perfusion ]Peritoneal to plasma area under the curve (AUC) ratio of ultrafiltrated cisplatin concentrations
- Pharmacokinetic advantage 2 [ Time Frame: During the HIPEC up to 1 hour from the completion of perfusion ]Peritoneal to plasma area under the curve (AUC) ratio of total protein bound cisplatin concentrations
- Impact of high intra-abdominal pressure on anesthesiologic parameters 1 [ Time Frame: Intraoperative phase ]Mean arterial pressure (mmHg)
- Impact of high intra-abdominal pressure on anesthesiologic parameters 2 [ Time Frame: Intraoperative phase ]Heart rate (beats per minute)
- Impact of high intra-abdominal pressure on anesthesiologic parameters 3 [ Time Frame: Intraoperative phase ]Central venous pressure (mmHg)
- Impact of high intra-abdominal pressure on anesthesiologic parameters 4 [ Time Frame: Intraoperative phase ]Cardiac index
- Impact of high intra-abdominal pressure on anesthesiologic parameters 5 [ Time Frame: Intraoperative phase ]Arterial oxygen saturation (PaO2)
- Impact of high intra-abdominal pressure on anesthesiologic parameters 6 [ Time Frame: Intraoperative phase ]Central venous oxygen saturation (ScvO2)
- Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 1 [ Time Frame: within 30 days after surgery ]Surgical complications (NCI CTCAEv3)
- Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 2 [ Time Frame: within 30 days after surgery ]Systemic toxicity (NCI CTCAEv3)
- Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 3 [ Time Frame: within 30 days after surgery ]Mortality
Original Secondary Outcome: Same as current
Information By: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Dates:
Date Received: October 7, 2016
Date Started: December 2014
Date Completion: June 2017
Last Updated: October 27, 2016
Last Verified: October 2016
